Thrombocytosis, methotrexate, and citrovorum factor

REFCOR guidelines on the management of olfactory neuroblastoma: A formalized expert consensus.

European annals of otorhinolaryngology, head and neck diseases·2026

Sinonasal squamous cell carcinoma: REFCOR guidelines for diagnosis, treatment and follow-up.

European annals of otorhinolaryngology, head and neck diseases·2026

French-language adaptation and linguistic validation of the ETDQ-7 Eustachian tube dysfunction assessment questionnaire following COSMIN guidelines.

European annals of otorhinolaryngology, head and neck diseases·2026

REFCOR guidelines for sinonasal adenocarcinoma.

European annals of otorhinolaryngology, head and neck diseases·2026

REFCOR guidelines for sinonasal adenoid cystic carcinoma.

European annals of otorhinolaryngology, head and neck diseases·2026

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

European annals of otorhinolaryngology, head and neck diseases·2026

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

No Germs, Just Cytokines: A Case of Immunotherapy-Induced Hemophagocytic Lymphohistiocytosis Masquerading as Neutropenic Sepsis in a Patient With Inflammatory Breast Cancer.

Cureus·2026

LigaSure™ Hemorrhoidectomy for Complex Grade III Hemorrhoidal Disease: A Prospective, Single-Center, Cohort Study.

Cureus·2026

Study on the predictive value of femoral head HU values in hip fractures.

Frontiers in surgery·2026

Atrial volume reduction correlates with early improvement in hemorrhage-associated normal pressure hydrocephalus-a 3D computed tomography volumetric study.

Frontiers in neurology·2026

Radially adjustable Tigertriever demonstrates higher reperfusion compared to self-expanding stent-retrievers during mechanical thrombectomy of large vessel occlusions: a systematic review and meta-analysis.

Frontiers in neurology·2026

Diabetes-duration-related shifts in inflammation-resolving lipid mediator signatures and their association with 3-month functional outcome in large artery atherosclerotic stroke.

Frontiers in neurology·2026

Related Experiment Videos

Thrombocytosis, methotrexate, and citrovorum factor

Related Concept Videos

REFCOR guidelines on the management of olfactory neuroblastoma: A formalized expert consensus.

Sinonasal squamous cell carcinoma: REFCOR guidelines for diagnosis, treatment and follow-up.

French-language adaptation and linguistic validation of the ETDQ-7 Eustachian tube dysfunction assessment questionnaire following COSMIN guidelines.

REFCOR guidelines for sinonasal adenocarcinoma.

REFCOR guidelines for sinonasal adenoid cystic carcinoma.

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

No Germs, Just Cytokines: A Case of Immunotherapy-Induced Hemophagocytic Lymphohistiocytosis Masquerading as Neutropenic Sepsis in a Patient With Inflammatory Breast Cancer.

LigaSure™ Hemorrhoidectomy for Complex Grade III Hemorrhoidal Disease: A Prospective, Single-Center, Cohort Study.

Study on the predictive value of femoral head HU values in hip fractures.

Atrial volume reduction correlates with early improvement in hemorrhage-associated normal pressure hydrocephalus-a 3D computed tomography volumetric study.

Radially adjustable Tigertriever demonstrates higher reperfusion compared to self-expanding stent-retrievers during mechanical thrombectomy of large vessel occlusions: a systematic review and meta-analysis.

Diabetes-duration-related shifts in inflammation-resolving lipid mediator signatures and their association with 3-month functional outcome in large artery atherosclerotic stroke.

Related Experiment Videos

Thrombocytosis, methotrexate, and citrovorum factor

Related Concept Videos

Related Articles